Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis

被引：0
|
作者：
Selmaj, K. W. [1 ,2 ]
Ziemssen, T. [3 ]
Comi, G. [4 ,5 ]
Hartung, H. -P. [6 ,7 ,8 ,9 ]
Singal, M. [10 ]
Riolo, J. V. [10 ]
Cheng, C. -Y. [10 ]
Sheffield, J. K. [10 ]
Minton, N. [10 ]
Vermersch, P. [11 ]
Cree, B. A. C. [12 ]
机构：
[1] Ctr Neurol, Lodz, Poland
[2] Univ Warmia & Mazury, Dept Neurol, Coll Medicum, Olsztyn, Poland
[3] Univ Hosp Dresden, Dept Neurol, Ctr Clin Neurosci, Carl Gustav Carus Univ Clin, Dresden, Germany
[4] Univ Vita Salute San Raffaele, Milan, Italy
[5] Casa Cura Policlin, Milan, Italy
[6] Heinrich Heine Univ, Med Fac, Dept Neurol, Dusseldorf, Germany
[7] Univ Sydney, Brain & Mind Ctr, Sydney, Australia
[8] Med Univ Vienna, Dept Neurol, Vienna, Australia
[9] Palacky Univ Olomouc, Olomouc, Czech Republic
[10] Bristol Myers Squibb, Princeton, NJ USA
[11] Univ Lille, Inserm UMR 1172, CHU Lille, FHU Precise, Lille, France
[12] Univ Calif San Francisco, Weill Inst Neurosci, Dept Neurol, San Francisco, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P732
引用
收藏
页码：641 / 642
页数：2
相关论文
共 50 条
  • [1] Safety patterns with ozanimod in phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. P.
    Singal, M.
    Thorpe, A.
    Riolo, J. V.
    Cheng, C. Y.
    Sheffield, J. K.
    Krakovich, A.
    Vermersch, P.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 324 - 324
  • [2] Relationship between infections and absolute lymphocyte count during phase 3 and open-label extension trials of ozanimod in patients with relapsing multiple sclerosis
    Hartung, H. -P.
    Steinman, L.
    Bar-Or, A.
    Sheffield, J. K.
    Harris, S.
    Riolo, J. V.
    Cheng, C. -Y.
    Silva, D.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 622 - 622
  • [3] Relationship Between Infections and Absolute Lymphocyte Count During Phase 3 and Open-label Extension Trials of Ozanimod in Patients With Relapsing Multiple Sclerosis
    Hartung, Hans-Peter
    Steinman, Lawrence
    Bar-Or, Amit
    Sheffield, James K.
    Harris, Sarah
    Riolo, Jon V.
    Cheng, Chun-Yen
    Silva, Diego
    Cree, Bruce A. C.
    NEUROLOGY, 2023, 100 (17)
  • [4] Hepatic safety of ozanimod in relapsing multiple sclerosis in the DAYBREAK open-label extension study
    Selmaj, K.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Afsari, S.
    Shi, F.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 608 - 609
  • [5] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in daybreak: an open-label extension study of ozanimod phase 1-3 trials
    Selmaj, K.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D.
    Hartung, H. P.
    Montalban, X.
    Havrdova, E.
    Sheffield, J.
    Chen, T.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J.
    Cree, B.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 223 - 223
  • [6] Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis
    Hartung, Hans-Peter
    Steinman, Lawrence
    Bar-Or, Amit
    Sheffield, James
    Harris, Sarah
    Riolo, Jon
    Cheng, Chun-Yen
    Reardon, Jennifer
    Thorpe, Andrew
    Cree, Bruce
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 354 - 354
  • [7] Update on Hepatic Safety of Ozanimod in Relapsing Multiple Sclerosis in the DAYBREAK Open-Label Extension Trial
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H. P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Thorpe, A.
    Riolo, J. V.
    Krakovich, A.
    Cheng, C. Y.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 325 - 326
  • [8] Ozanimod Efficacy in Relapsing Multiple Sclerosis Supported by Open-Label Long-Term Extension of Two Phase 3 Trials
    Steinman, Lawrence
    Comi, Giancarlo
    Cree, Bruce A. C.
    Bar-Or, Amit
    Selmaj, Krzysztof W.
    Arnold, Douglas L.
    Hartung, Hans-Peter
    Montalban, Xavier
    Havrdova, Eva K.
    Sheffield, James K.
    Huang, Vivian
    Silva, Diego
    Kappos, Ludwig
    Cohen, Jeffrey A.
    NEUROLOGY, 2019, 92 (15)
  • [9] Long-term Safety and Tolerability of Ozanimod by Age Category in Patients With Relapsing Multiple Sclerosis From Two Phase 3 Trials and an Open-Label Extension Study
    Selmaj, K. W.
    Cohen, J. A.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H.
    Montalban, X.
    Kappos, L.
    Sheffield, J. K.
    Krakovich, A.
    Cheng, C.
    Riolo, J.
    Silva, D.
    Cree, B. A.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 56 - 57
  • [10] Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
    Hartung, Hans-Peter
    Steinman, Lawrence
    Bar-Or, Amit
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Harris, Sarah
    Reardon, Jennifer
    Thorpe, Andrew
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1016 - 1017
12345